Semaglutide
GLP-1 Receptor Agonist
Best For
Sustained weight management, metabolic health optimization, cardiovascular risk reduction
14.9%
Average body weight loss in STEP 1 trial
20%
Reduction in major cardiovascular events (SELECT)
68wk
Duration of landmark efficacy trials
How It Works
Semaglutide is a long-acting GLP-1 receptor agonist that binds to incretin receptors on pancreatic beta cells and hypothalamic neurons. By activating GLP-1 receptors in the arcuate nucleus, it suppresses appetite signaling while simultaneously delaying gastric emptying — prolonging satiety after meals. The compound also improves peripheral insulin sensitivity by enhancing glucose-dependent insulin secretion and suppressing glucagon release, which collectively shift the body toward sustained fat oxidation.
Key Research Areas
Appetite Suppression
Reduces caloric intake by 20-35% through central hypothalamic signaling
Body Weight Reduction
Clinical trials demonstrate 14.9% average total body weight loss over 68 weeks
Insulin Sensitivity
Lowers fasting glucose and HbA1c by enhancing glucose-dependent insulin release
Cardiovascular Risk
SELECT trial showed 20% reduction in major adverse cardiovascular events
Research Highlights
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Featured Research
Formulation Notes
Common concentrations referenced in published clinical studies:
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
Tirzepatide
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgRetatrutide
Triple GLP-1/GIP/Glucagon Agonist
- Broadest receptor pathway activation — 3 mechanisms at once
- Enhances daily energy expenditure and lean mass preservation
Reference Codes
[RT20]20mg[RT30]30mgAOD-9604
HGH Fragment 177-191
- Isolates the fat-loss mechanism of growth hormone without systemic side effects
- Granted GRAS status by the FDA in 2007 for oral anti-obesity applications
Reference Codes
[5AD]5mgEvidence reviewed: March 2026